고형암 표적 단백질 시장 : 적응증별, 표적 클래스별, 치료법별, 작용기서별, 국가별, 지역별 - 세계 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Solid Tumors Target Proteins Market size was valued at US$ 1,678.23 Million in 2025, expanding at a CAGR of 10.2% from 2026 to 2033.

Solid tumors are abnormal growths of cancer cells that develop on or in different organs and tissues such as the breast, lungs, prostate, colon, liver and pancreas. In turn, target proteins are dysregulated, amplified, mutated or overexpressed in malignant cells and are contributing to tumor growth, proliferation, survival, invasion, angiogenesis and immune escape and are serving as therapeutic targets for treating such disorders. Some of the many target proteins are HER2 (ERBB2), EGFR, VEGF/VEGFR, PD-L1, BRAF, MET, ALK, ROS1, KRAS, PI3K, CDK4/6, and PARP. These molecules can be precisely targeted using monoclonal antibodies, antibody-drug conjugates, small molecule inhibitors, and other types of therapeutic agents, which will kill cancer cells or hinder the capacity of cancer cells to proliferate and spread. Thus, target proteins in solid tumors are crucial in the development of extremely powerful and specific treatments for malignancies with a personalized view of each patient's unique molecular profile.

Solid Tumors Target Proteins Market- Market Dynamics

Rising prevalence of solid tumors drives market growth

The rising incidence of solid tumors is a significant factor driving the solid tumors target proteins market. Increasing diagnosed cancer patients suffering from lung, breast, colon and rectum, prostate, liver, stomach, and pancreatic cancer and others are expected to propel the demand for molecular diagnostic tests and targeted therapies. As per the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), the overall number of cancer cases worldwide in the latest report reaching around 20.6 million new cases. Moreover, cancer is the second-highest cause of death, leading to nearly 10 million deaths per year. WHO and IARC estimate that the number of cancer incidences will surge to almost 35 million cases per year by 2050, implying a significant rise in the number of cancer patients.

Solid Tumors Target Proteins Market- Segmentation Analysis:

The Global Solid Tumors Target Proteins Market is segmented on the basis of indication, target class, therapeutic modality, mechanism of action, and Region.

The market is divided into five categories based on indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. The Breast Cancer sector is expected to observe significant revenue growth in the Solid Tumors Target Proteins market owing to the increasing incidence of breast cancer. For instance, according to the WHO, in 2024, there were an estimated 2.4 million women diagnosed with breast cancer and 694 000 deaths globally. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life.

The market is divided into four categories based on therapeutic modality: Antibody Drug Conjugates, Car T, Monoclonal Antibodies and Small Molecules. The Antibody Drug Conjugates segment would witness the highest revenue growth. The growth is attributed to the fact that Antitumor Antibody-Drug Conjugates (ADCs) directly link the discovery of tumor-associated proteins to their targets by using antibodies coupled to cytotoxic drugs via linkers. These drugs have the ability to selectively bind to specific proteins in tumor cells so that drugs can be delivered specifically into the cancerous cells. Therefore, it allows developing treatment for various diseases such as HER2 and TROP-2 positive cancers. The rapid rise in the development and approval of ADCs is projected to boost the demand for target proteins and propel the commercialization of solid-tumor therapeutics market. More than ten antibody drug conjugates have been approved by the U.S Food and Drug Administration (FDA) across indications as of February 2025, suggesting that there is a high adoption rate of ADCs in the treatment of cancer.

Solid Tumors Target Proteins Market- Geographical Insights

North America is expected to remain the leading revenue-generating region for the solid tumors target proteins market during the forecast period, attributed to high prevalence of solid-tumor patients, advanced cancer diagnosis, high-precision treatment strategies, and rising pharmaceutical and biotechnology activities. The U.S. is estimated to witness 2,041,910 new cancer cases in 2025, as reported by the National Cancer Institute of the U.S. Some of the most common types of cancer across the U.S. include breast cancer, prostate cancer, lung, and bronchus cancer, colorectal cancer, pancreatic cancer, kidney cancer, and liver cancer.

US Solid Tumors Target Proteins Market- Country Insights

The U.S market for solid tumors target proteins is witnessing growth due to the rising number of FDA approvals of molecularly targeted therapies against cancer. The commercial value of proteins and biomarkers like HER2, EGFR, KRAS, BRAF, RET, MET, ALK, ROS1, PD-L1, TROP-2, and PSMA is on the rise. According to FDA data, the U.S oncology drug and biologic development environment is robust, as the FDA's Office of Hematology and Oncology Products approved 89 oncology drugs and biologics, including 19 new molecular entities/new biologics and 34 new indications for drugs already on the market in 2024.

Solid Tumors Target Proteins Market- Competitive Landscape:

The solid tumors target proteins market is highly competitive and innovative. The leading pharmaceutical and biotechnology companies are engaged in the discovery and validation of tumor associated proteins, as well as in the development of the corresponding therapeutics; antibody drug-conjugated (ADC) therapeutics, monoclonal antibodies, kinase inhibitors, and companion diagnostics. The companies are focusing on clinically validated tumor-associated targets to increase the likelihood of success during the development process. Thus, the competition is intense, and the key targets are HER2, TROP-2, EGFR, KRAS, ROS1, RET, MET, PD-L1, PSMA, and ESR1. The validation of these tumor-associated proteins facilitates the approval of therapeutics, as well as an expansion into other fields of solid tumors.

Recent Developments:

In June 2026, Johnson & Johnson announced an opportunity inviting global innovators to submit ideas for novel, differentiated technologies with the potential to deliver superior safety and efficacy in the treatment of solid tumors.

In October 2025, AbbVie announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis(TM) (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Roche Holding AG / Genentech
• Pfizer Inc.
• Eli Lilly and Company
• Daiichi Sankyo Company, Limited
• Novartis AG
• Johnson & Johnson
• Amgen Inc.
• AbbVie Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Regeneron Pharmaceuticals, Inc.
• Sanofi
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.
• Exelixis, Inc.
• BeOne Medicines Ltd.
• Others

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY TARGET CLASS- MARKET ANALYSIS, 2020 - 2033

• Checkpoint Inhibitors
• Ctla-4
• Pd-1
• Pd-L1
• Dna Repair Proteins
• Growth Factor Receptors
• Egfr
• Her2
• Vegfr
• Kinase Inhibitors
• Serine Threonine Kinase Inhibitors
• Tyrosine Kinase Inhibitors
• Nuclear Receptors

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2020 - 2033

• Antibody Drug Conjugates
• Car T
• Monoclonal Antibodies
• Chimeric
• Fully Human
• Humanized
• Small Molecules

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2020 - 2033

• Allosteric Inhibitors
• Dna Damage Agents
• Hormone Receptor Antagonists
• Immune Checkpoint Blockers
• Receptor Tyrosine Kinase Inhibitors

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Solid Tumors Target Proteins Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Solid Tumors Target Proteins Market Snippet by Indication
  • 2.1.2. Solid Tumors Target Proteins Market Snippet by Target Class
  • 2.1.3. Solid Tumors Target Proteins Market Snippet by Therapeutic Modality
  • 2.1.4. Solid Tumors Target Proteins Market Snippet by Mechanism of Action
  • 2.1.5. Solid Tumors Target Proteins Market Snippet by Country
  • 2.1.6. Solid Tumors Target Proteins Market Snippet by Region
• 2.2. Competitive Insights

3. Solid Tumors Target Proteins Key Market Trends

• 3.1. Solid Tumors Target Proteins Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Solid Tumors Target Proteins Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Solid Tumors Target Proteins Market Opportunities
• 3.4. Solid Tumors Target Proteins Market Future Trends

4. Solid Tumors Target Proteins Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Solid Tumors Target Proteins Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Solid Tumors Target Proteins Market Landscape

• 6.1. Solid Tumors Target Proteins Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Solid Tumors Target Proteins Market - By Indication

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
  • 7.1.2. Breast Cancer
  • 7.1.3. Ovarian Cancer
  • 7.1.4. Lung Cancer
  • 7.1.5. Colorectal Cancer
  • 7.1.6. Prostate Cancer
  • 7.1.7. Others

8. Solid Tumors Target Proteins Market - By Target Class

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Target Class, 2025 & 2033 (%)
  • 8.1.2. Checkpoint Inhibitors
    • 8.1.2.1. Ctla-4
    • 8.1.2.2. Pd-1
    • 8.1.2.3. Pd-L1
  • 8.1.3. Dna Repair Proteins
  • 8.1.4. Growth Factor Receptors
    • 8.1.4.1. Egfr
    • 8.1.4.2. Her2
    • 8.1.4.3. Vegfr
  • 8.1.5. Kinase Inhibitors
    • 8.1.5.1. Serine Threonine Kinase Inhibitors
    • 8.1.5.2. Tyrosine Kinase Inhibitors
  • 8.1.6. Nuclear Receptors

9. Solid Tumors Target Proteins Market - By Therapeutic Modality

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Therapeutic Modality, 2025 & 2033 (%)
  • 9.1.2. Antibody Drug Conjugates
  • 9.1.3. Car T
  • 9.1.4. Monoclonal Antibodies
    • 9.1.4.1. Chimeric
    • 9.1.4.2. Fully Human
    • 9.1.4.3. Humanized
  • 9.1.5. Small Molecules
  • 9.1.6. Others

10. Solid Tumors Target Proteins Market - By Mechanism of Action

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Mechanism of Action, 2025 & 2033 (%)
  • 10.1.2. Allosteric Inhibitors
  • 10.1.3. Dna Damage Agents
  • 10.1.4. Hormone Receptor Antagonists
  • 10.1.5. Immune Checkpoint Blockers
  • 10.1.6. Receptor Tyrosine Kinase Inhibitors
  • 10.1.7. Others

11. Solid Tumors Target Proteins Market- By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Solid Tumors Target Proteins Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Solid Tumors Target Proteins Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.17. Denmark
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.17.3. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.17.4. Denmark Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.17.5. Denmark Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.17.6. Denmark Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3.18. Rest of Europe
    • 11.3.18.1. Overview
    • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Solid Tumors Target Proteins Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.16. Taiwan
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.16.3. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.16.4. Taiwan Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.16.5. Taiwan Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.16.6. Taiwan Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.17. Vietnam
    • 11.4.17.1. Overview
    • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.17.3. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.17.4. Vietnam Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.17.5. Vietnam Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.17.6. Vietnam Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4.18. Rest of APAC
    • 11.4.18.1. Overview
    • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.18.3. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.18.4. Rest of APAC Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.18.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.18.6. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. Solid Tumors Target Proteins Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. Solid Tumors Target Proteins Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.14. Iran
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.14.3. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.14.4. Iran Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.14.5. Iran Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.14.6. Iran Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.15. Qatar
    • 11.6.15.1. Overview
    • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.15.3. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.15.4. Qatar Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.15.5. Qatar Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.15.6. Qatar Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6.16. Rest of MEA
    • 11.6.16.1. Overview
    • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.16.3. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.16.4. Rest of MEA Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.16.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.16.6. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Solid Tumors Target Proteins Industry

• 12.1. Competitive Benchmarking
  • 12.1.1. Competitive Dashboard
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. AstraZeneca PLC
  • 12.2.2. Bristol-Myers Squibb Company
  • 12.2.3. Merck & Co., Inc.
  • 12.2.4. Roche Holding AG / Genentech
  • 12.2.5. Pfizer Inc.
  • 12.2.6. Eli Lilly and Company
  • 12.2.7. Daiichi Sankyo Company, Limited
  • 12.2.8. Novartis AG
  • 12.2.9. Johnson & Johnson
  • 12.2.10. Amgen Inc.
  • 12.2.11. AbbVie Inc.
  • 12.2.12. Bayer AG
  • 12.2.13. Boehringer Ingelheim International GmbH
  • 12.2.14. GlaxoSmithKline plc
  • 12.2.15. Regeneron Pharmaceuticals, Inc.
  • 12.2.16. Sanofi
  • 12.2.17. Takeda Pharmaceutical Company Limited
  • 12.2.18. Gilead Sciences, Inc.
  • 12.2.19. Exelixis, Inc.
  • 12.2.20. BeOne Medicines Ltd.
  • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us